צמיחת רווח נקי למניה משנה לשנה ב-12 החודשים האחרונים amylyx.com (AMLX)

Amylyx Pharmaceuticals (AMLX) is automating the synthesis of Alzheimer's drugs, leveraging algorithms and medical oversight. However, a narrow portfolio and insurance complexities create financial risks. Trial failures led to a loss of the patient base and the drug's withdrawal from the market. The quarterly EPS growth marker visualizes current volatility, where the -3.70 metric determines this level.

This metric reflects the rate of change in net income per common share. The algorithm calculates the percentage deviation of the current EPS from the same period last year. By analyzing quarterly earnings per share (EPS) growth, an investor assesses the efficiency of capital generation. For Amylyx Pharmaceuticals (AMLX), this trend reflects the success of developing drugs against neurodegeneration. Portfolio diversification within the rare disease niche directly impacts the volatility of this metric.